A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients

NCT03945721 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer
Residual Disease

Interventions

DRUG: Niraparib
RADIATION: Radiation Therapy

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]